Purpose of Review Heart failure (HF) continues to be a public health burden despite advances in therapy, and the natriuretic peptide (NP) system is clearly of critical importance in this setting, spawning valuable diagnostic and prognostic testing, such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), as well as current and future therapeutics, including recombinant natriuretic peptides (e.g., carperitide, nesiritide) and recently sacubitril, which inhibits the key clearance mechanism for NPs. This article intends to summarize the existing evidence for the role of NP system genetic variation on cardiovascular phenotypes relevant to HF with particular focus on the potential impact on pharmacologic therapies. Recent Findings Several genes in NP system have been interrogated, in many cases genetic variation impacting protein quantity and function or related disease states. Recent data supports genetic variants potentially impacting pharmacokinetics or dynamics of medications targeting the pathway. Summary Growing evidence indicates the importance of genetic variation to the functioning of the NP system and its pharmacologic manipulation.
Introduction
Heart failure (HF) is a primary public health burden with nearly 1 million new HF cases annually. It is projected that the prevalence of HF will increase by 46% from 2012 to 2030, resulting in more than eight million adults becoming burdened by the disease. Despite current advances in the diagnosis and management of HF, mortality remains high with an estimated 40-50% of patients dying within 5 years of diagnosis [1] . This is not to say that we have not been successful in generating new therapies. There are now numerous classes of medications that improve survival in heart failure; however, this success also brings challenges in terms of getting all patients on all therapies. More usually if one cannot get the patient on all therapies, how to prioritize and dose each medication optimally is not clear. As a result, new approaches to improve and personalize therapy are clearly needed but still not established. The natriuretic peptide (NP) pathway is one key counter-regulatory system which is critical to the cardiovascular system function generally and to the heart failure disease state in particular. The NP system has been investigated in terms of diagnostic testing [2, 3] , prognostic assessment [4] [5] [6] , and multiple therapeutic strategies [7] [8] [9] [10] [11] . This area of investigation continues to develop at a rapid pace. Simultaneously, growing evidence of important variations in the NP pathway has accumulated, including a specific role of genetic variation impacting system functioning and potentially drug therapy [12] [13] [14] [15] . In this article, we briefly review the key gene/proteins involved and then summarize the known and suspected genomic impact on each, outlining the potential clinical relevance.
perturbed in the setting of HF. The NP system is the subject of several excellent reviews [16, 17] , and we will only briefly outline it here. The cardiac effects of NPs include diuresis, natriuresis, and vasodilation which leads to lower blood pressure and protective effects on the myocardium. [16, [18] [19] [20] [21] [22] [23] . Importantly, NPs are also known to antagonize the effects of inflammatory cytokines, the renin-angiotensin-aldosterone axis, and the transforming growth factor beta pathway, acting as a key counter-regulatory system in the setting of HF when many of these adverse pathways are over-activated [24] [25] [26] .
The NP system is comprised of three main naturally occurring peptides; atrial NP (ANP), B-type NP (BNP), and C-type NP (CNP). There are multiple versions of each, some varying by organ or tissue location. These NPs are initially produced as precursor peptides by the genes natriuretic peptide precursor-A (NPPA), NPPB, and NPPC, respectively.
ANP is mainly secreted in the atria in response to myocardial stretch. Transmembrane serine protease (a.k.a corin) cleaves the Pro-peptide into the 28-amino acid active form [27] . BNP which was initially extracted from porcine brain "hence the name Brain NP" [28] is mostly secreted from ventricular myocytes in response to myocardial stress such as in infarction and HF. It is secreted as preprohormone that is eventually sliced by corin or furin to give initially Pro-BNP, then the 32-amino acid active form plus N-terminal proBNP (NT-proBNP) [29] . ANP, BNP, and NT-proBNP are all elevated in patients with HF. However, BNP tends to be preferred as a prognostic factor in clinical practice given their greater stability [30] . CNP is mostly excreted from endothelial cells in response to different cytokines and is also found in the brain and other tissues. Intracellular furin cleaves ProCNP into the 53-amino acid active form [31, 32] . Unlike the previous NPs, CNP levels are usually not elevated in patients with HF; its role in heart failure is not entirely understood [33] .
The NPs bind to three different receptors, NP receptor A (NPRA), NPRB, and NPRC. NPRA and NPRB are both transmembrane guanylate cyclases, which when bound to NP, become active leading to increased intracellular levels of cyclic guanosine monophosphate (cGMP), which is thought to be the primary second messenger responsible for most physiological effects exerted by the NP system [34] . NPRC is similar in the extracellular domain but does not possess any intrinsic enzymatic activity and is thought to be mainly involved in the clearance of NPs; binding to NPRC ultimately leads to internalization and lysosomal degradation of peptides [35] . Another important mechanism to clear NPs is via membrane bound metallo-endopeptidase, also known as neprilysin (NEP), which has a broad tissue distribution including the lungs and kidneys and acts on a variety of peptides [36] .
Various mechanisms have been proposed to account for the diminished effectiveness of the NPs in the setting of HF, possibly due to decreased availability of biologically active NPs either by reduced production or increased clearance of NPs [37] . Alternatively, diminished target organ responsiveness could occur perhaps via decreased receptor expression or inhibition of downstream signaling. Moreover, activation of other neurohormonal systems like RAAS, endothelin-1, and sympathetic system in the setting of HF, can also counteract NP system, which generally has opposing effects and thus decreases its effectiveness [38] .
Impact of Genetic Variation in the Natriuretic Peptide System
Natriuretic Peptide Precursor A and Natriuretic Peptide Precursor B Genes
Numerous studies have identified different single-nucleotide polymorphisms (SNPs) in the NPPA and NPPB genes. One of the most widely studied SNPs is a variant in the promoter region called rs198389. The minor allele of rs198389 SNP has been shown to be associated with higher levels of BNP and its precursor NT-proBNP [14, [39] [40] [41] [42] [43] [44] . Further studies showed that this is reflected clinically by leading to a lower likelihood of ventricular dysfunction in patients after coronary artery bypass grafting [45] , lower readmission rates after discharge, and a lower risk of future type 2 diabetes mellitus [46, 47] . Also, in a meta-analysis, African Americans with the minor allele had lower systolic BP (SBP) [44] . Similar studies have been conducted on minor alleles of SNPs in the NPPA gene, which revealed increased atrial NP and BNP levels; additionally, minor alleles of ANP gene SNPs have been associated with lower blood pressure in white individuals [45, 48] . NPPA polymorphism studies were smaller and had limited follow-up when compared to studies conducted on NPPB gene SNPs.
Natriuretic Peptide Precursor C Gene
Few studies investigated NPPC and its relationship to cardiovascular diseases. The earliest was conducted on Japanese population which identified a gene variant in the threeuntranslated region of NPPC that was associated with high blood pressure, suggesting that NPPC may also play a role in the development of hypertension [49] . In another study examining other SNPs, minor alleles of both rs11079028 and rs4796751 SNPs were associated with increased levels of circulating CNP, and additionally greater concentrations of BNP and NT-proBNP. Neither had an association with high blood pressure [43] . The rs700923 minor allele was shown to increase the risk of diastolic hypertension in Chinese population. In another study, the same SNP was associated with higher risk of left ventricular dysfunction after coronary artery bypass graft. This observation, taken together with our findings, supports that the NPRC rs700923 polymorphism might be a susceptible locus for cardiovascular phenotypes, and warrants further investigation [45] .
CORIN and FURIN Genes
Corin is a serine protease that is mainly found in the myocardium and whose main role is to cleave and thus activate proNPs, principally converting pro-ANP to active ANP [50] . Similarly, it can also act on pro-BNP to produce biologically active BNP [27, 51] . Interestingly, serum corin levels have been shown to decrease over time during progression of heart failure [52] , consistent with the observations of relatively greater abundance of immature BNP forms that are less active biologically. Even outside of the setting of HF, its activity is likely important for cardiovascular homeostasis; for example, in patients with coronary disease, corin levels are inversely correlated to adverse clinical outcomes [53] .
Growing evidence indicates that genetic variation in CORIN may result in alterations in the function of the expressed protein and even clinical phenotypes in humans. An excellent example is the CORIN T555I/Q568P variant which has been linked to both altered protein function and clinical phenotypes. Interestingly, the variant allele is particularly common among African Americans; roughly, 10-12% of African Americans are carriers of the variant allele [54] . Several studies in African Americans have linked the variant allele to higher levels of pro-ANP and pro-BNP (consistent with defective or reduced corin protein function) and increased risk of cardiovascular disease, specifically hypertension and heart failure [54] [55] [56] [57] . Completing this line of evidence is a functional study using a transgenic mouse model; mice expressing the variant allele developed salt-sensitive hypertension and cardiac hypertrophy, whereas the mice expressing the wild-type allele did not [58] . The variant allele mice also had higher levels of precursor proteins and lower levels of mature ANP and BNP, congruent with results of the human studies. Parallel to the above, a rare CORIN sequence variant resulting in coding change, R539C, was described in a Chinese family which had lower ANP and BNP in the serum familial hypertension, consistent with hypofunction of corin [59] . While these data make clear that genetic variation in corin can impact function and even disease states, there are no studies demonstrating specific pharmacologic interactions that we could identify. However, one possible implication of these data is that genetic variations leading to hyperfunctioning could be beneficial, and perhaps, corin should be explored as a bio-target.
Another key activity enzyme in the NP pathway is furin. It is a pro-protein convertase (paired basic amino acid cleaving enzyme) which is involved in the processing of precursor proteins into their active forms and is very broadly expressed in different tissues and acts on a wide array of substrates (proparathyroid hormone, transforming growth factor beta 1 precursor, proalbumin, others). It is encoded by the FURIN gene, located on the long arm of chromosome 15 (15q26.1). FURIN has received relatively less investigative attention concerning NPs and HF, but there are some studies indicating an impact of genomic variation. Several single-nucleotide polymorphisms (SNPs) in FURIN are associated with hypertension [60] [61] [62] . For instance, it has been shown that rs2071410 is associated with hypertension in Chinese [60] . Another study in a different Chinese cohort found that rs2071410 was strongly associated with the occurrence of transient ischemic attacks [63] . Pharmacogenomic impact of FURIN in the setting of HF remains to be demonstrated, but interestingly appears to have an important role in atherosclerosis and may soon be investigated there as a potential drug or precision medicine target [64] .
Natriuretic Peptide Receptor 1 and Natriuretic Peptide Receptor 2
Since natriuretic peptide receptors (NPR) A and B are the key effector receptors for ANP and BNP and also the main drug target for carperitide, nesiritide, and other agents, the genes encoding them (NPR1 and NPR2, respectively) are obvious pharmacogenetic candidate genes. Beginning with functional and disease phenotype associations and moving into pharmacogenetic studies, there is a line of evidence that genetic variation in these two genes impact NP system function, but pharmacogenetic associations are not convincing, and thus whether (and how) this may translate into actionable precision, medicine remains to be determined.
Several studies have identified SNPs in the NPR1 gene associated with cardiovascular phenotypes. A relatively early example published in 2003 showed that NPR1 variant alleles were associated with the expression of NPRA as well as a higher risk for essential hypertension [65] . Subsequently, sequence variants in the 5′-flanking region of NPRA gene were associated with hypertension and stroke [66, 67] . Similar to other examples discussed, ancestral population can often impact allele frequency and the relationship of genetic variants to phenotype. In the case of NPR1, there has been substantial investigation in the Japanese population, producing some of the most interesting associations. In studies in a Japanese cohort, two genetic variants in NPR1, a missense mutation in exon 3 and a deletion in 5′-flanking region, were associated with increased risk of essential hypertension [68, 69] . The 5′ deletion was also shown to affect ventricular remodeling and was associated with cardiac hypertrophy among patients with hypertension [70] .
Our group sought to investigate the functional impact of genetic sequence variants as well as specific pharmacogenetic effects. First, we tested the association of genetic polymorphisms in NPR1 with gene and protein expression, finding that certain variants in NPR1 were associated with altered expression at both the mRNA and the protein levels [71] . Following this, we performed a study in humans with HF, infusing nesiritide and quantifying the drug response in terms of changes in cGMP plasma level as well as blood pressure. Interestingly, we found no significant association (once corrected for multiple comparisons) of gene variants with the response to nesiritide [72] .
Regarding NPR2, its product NPRB (a.k.a GC-B) was not thought to be as physiologically important as NPRA which could explain the relatively fewer investigations into its genetic variation. Nonetheless, in another study among Japanese, a novel GT repeat in intron 2 of the NPR2 gene was associated with risk for hypertension [73] . Similarly to the above, in a study done by our group, NPR2 gene expression and NPRB protein quantity (in kidney tissue) were significantly impacted by genetic variation [71] . We also investigated whether genetic variation in NPR2 altered cGMP production or blood pressure change in humans with HF receiving nesiritide infusion. In contrast to the findings associating genetic variants with gene and protein expression (but congruent with similar experiments in NPR1), we did not find that genetic variants in NPR2 impacted nesiritide effect in terms of plasma cGMP or blood pressure change [72] .
Natriuretic Peptide Receptor 3
Natriuretic peptide receptor C, which is encoded by the NPR3 gene, is one of the key mechanisms for NP clearance. NPRC has significant homology to the other NPRs but lacks the intracellular guanylate cyclase domain that other NP receptors possess. It is mainly thought to be involved in the internalization and clearance of NPs. In a NPR3 knockout mouse model, NPs had longer half-life, lower blood pressure, and increased diuretic susceptibility [74] . Our group and others have investigated the impact of NPR3 genetic variation on NP system function, disease phenotypes, and even pharmacogenetic interactions.
Genetic sequence variation in NPR3 has been associated with cardiovascular phenotypes in multiple populations. Several publications have linked SNPs of NPR3 gene with blood pressure across a variety of settings, including varying ancestral populations and clinical circumstances [75] [76] [77] .
Other clinical phenotypes associated with NPR3 SNPs were left ventricular dysfunction following bypass grafting and increased risk for coronary artery disease [78, 79] . In sum, there are a number of studies indicating that genetic variation in NPR3 is related to clinical phenotype, suggesting it importantly effects NP system function.
Moving into the mechanistic support for genetic impact in NPR3 is another line of strong evidence. Older data indicated that a NPR3 promoter variant was associated with changes in BNP level [80] , a variant very close to some of the above that are associated with hypertension, providing evidence of mechanism of action. As proof of principle, a very compelling story was presented by Pereira et al. who systematically interrogated the gene, not only identifying many novel variants but examining the impact on protein function and establishing mechanism for the Arg146 variant [13] . Data from our lab also supports genetic variation in NPR3 impacting expression [71] . Taking this forward into true pharmacogenetics, we sought to test whether NPR3 genetic variation might impact the pharmacokinetics of infused nesiritide, since it acts as a clearance mechanism. Nesiritide was infused into patients with established HF, and baseline, steady state, and elimination levels of BNP were measured. The pharmacokinetic parameters of interest such as clearance rate, half-life, and elimination constant were tabulated and tested for association with genetic variants in NPR3. We found two SNPs (rs6880564, rs2062708) that were associated with the pharmacokinetics of infused nesiritide [81] .
Membrane Metallo-Endopepdtidase Gene
Membrane metallo-endopepdtidase, a.k.a neprilysin (NEP), neutral endopeptidase, enkaphalinase, and many other names, is a peptidase that cleaves (thus inactivating) a large number of peptide hormones. One well-known subgroup of its substrates is the NPs, including ANP and BNP, but it also acts on bradykinins and amyloid protein among others. In terms of BNP, NEP is one of the primary clearance mechanisms, and it is thought that greater than 50% of BNP is deactivated via NEP enzymatic cleavage. Thus, it has been investigated both in terms of its effects on NP levels and activity and is now a therapeutic target in its own right.
NEP is coded for by the gene membrane metalloendopepdtidase (MME). Genetic sequence variants in MME have been investigated in terms of protein abundance, BNP clearance rates, and cGMP production due to nesiritide. Our research group showed that MME gene expression and actual NEP protein content in kidney tissue samples were significantly associated with polymorphisms in MME [71] . We further demonstrated that genetic variants in MME were also associated with clearance rate of infused nesiritide [81] , as well as the associated changes in cGMP and blood pressure [72] . Interestingly, these various associations did not all align to a specific variant or region within the gene, but overall, the linkage block at the 3′-end of the gene appears to be area most likely to be involved in these differences.
Similarly, Pereira and colleagues identified several sequence variants that alter the activity and the quantity of NEP, performing more in depth functional studies. Most interesting of the variants explored was a coding variant, Met73Val, which was the most significantly associated with changes in NEP activity [82] . While these data are not definitive, taking together this line of evidence strongly suggests that genetic variation in MME likely impacts the NP system physiology and could have implications for the risk of HF development, disease progression in HF patients, and possibly therapeutics. This is particularly salient now when NEP inhibition is a proven strategy in the treatment of HF. The PARADIGM study was the pivotal clinical trial establishing dual-angiotensin receptor and NEP inhibition as a treatment strategy superior to ACE-I alone. There are no studies examining the impact of MME genetic variation on the effectiveness of sacubitril/valsartan, but data such as the above obviously begs that question.
Conclusion
Despite the failure of recombinant NP therapeutic strategies, the NP system remains a critical pathway for cardiovascular homeostasis and is particularly important in the setting of HF. It is clear that genetic variation in key genes can affect the NP system's function as well as impacting effect of drugs; this is specifically demonstrated in terms of the pharmacokinetics of infused NPs as well as some data indicating alteration of corresponding pharmacodynamics. While there are no examples of NP system pharmacogenomic interactions that currently have sufficient evidence for clinical implementation, this remains a fertile area, particularly in view of the benefits of NEP inhibitors.
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